RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication
Artículo científico (JournalArticle)
Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small cell lung cancer
[EN] The high resistance against current therapies found in non-small-cell lung cancer (NSCLC) has been associated to
cancer stem-like cells (CSCs), a population for which the identification of targets and biomarkers is still under
development. In this study, primary cultures from early-stage NSCLC patients were established, using sphere-forming
assays for CSC enrichment and adherent conditions for the control counterparts. Patient-derived tumorspheres
showed self-renewal and unlimited exponential growth potentials, resistance against chemotherapeutic agents,
invasion and differentiation capacities in vitro, and superior tumorigenic potential in vivo. Using quantitative PCR, gene
expression profiles were analyzed and NANOG, NOTCH3, CD44, CDKN1A, SNAI1, and ITGA6 were selected to distinguish
tumorspheres from adherent cells. Immunoblot and immunofluorescence analyses confirmed that proteins encoded
by these genes were consistently increased in tumorspheres from adenocarcinoma patients and showed differential
localization and expression patterns. The prognostic role of genes significantly overexpressed in tumorspheres was
evaluated in a NSCLC cohort (N = 661) from The Cancer Genome Atlas. Based on a Cox regression analysis, CDKN1A,
SNAI1, and ITGA6 were found to be associated with prognosis and used to calculate a gene expression score, named
CSC score. Kaplan¿Meier survival analysis showed that patients with high CSC score have shorter overall survival (OS)
in the entire cohort [37.7 vs. 60.4 months (mo), p = 0.001] and the adenocarcinoma subcohort [36.6 vs. 53.5 mo, p =
0.003], but not in the squamous cell carcinoma one. Multivariate analysis indicated that this gene expression score is
an independent biomarker of prognosis for OS in both the entire cohort [hazard ratio (HR): 1.498; 95% confidence
interval (CI), 1.167¿1.922; p = 0.001] and the adenocarcinoma subcohort [HR: 1.869; 95% CI, 1.275¿2.738; p = 0.001].
This score was also analyzed in an independent cohort of 114 adenocarcinoma patients, confirming its prognostic
value [42.90 vs. not reached (NR) mo, p = 0.020]. In conclusion, our findings provide relevant prognostic information
for lung adenocarcinoma patients and the basis for developing novel therapies. Further studies are required to identify
suitable markers and targets for lung squamous cell carcinoma patients., This work was supported by Fondo de Investigación Sanitaria, ISCIII (PI12-02838, PI12-00956, PI15-00753, PI15-00209), and Fundación Arnal Planelles. A. H.-P. and J.M.P.-S. are supported by Ministerio de Educación, Cultura y Deporte (FPU14/06911 and FPU13/02755, respectively).